查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798778

全球色素减退治疗市场的成长、规模和趋势分析：展望、竞争策略以及按治疗类型、适应症和地区分類的预测（截至 2034 年）

Global Hypopigmentation Disorder Treatment Market Growth, Size, Trends Analysis- By Treatment Type, By Disease Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 244 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年，全球色素减退治疗市场规模将达到 61.1 亿美元，预测期内的复合年增长率为 6.36%。

色素减退症的治疗着重于解决以黑色素（决定肤色的色素）减少或缺失为特征的疾病。常见疾病包括白斑症、白化症和发炎后色素减退症。治疗的目标是恢復色素沉着，改善外观，并提高整体生活品质。

阻碍因素：色素减退治疗市场面临许多障碍，可能会限制其成长。其中一大挑战是缺乏根治性方案，因为许多治疗方法旨在控制症状，而非提供永久性的缓解。患者对局部固醇和照光治疗等治疗方法的反应差异很大，难以确保疗效的一致性。

本报告调查了全球色素减退治疗市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争态势

  • 製造地、销售区域、产品类型分布
  • 併购、合作伙伴关係、产品发布和合作

第七章 全球色素减退治疗市场

  • 药物
    • 皮质类固醇
    • 促黑素细胞激素
    • 其他的
  • 按程式
    • 雷射治疗
    • 照光治疗
    • 微晶换肤
    • 其他的
  • 按最终用户
    • 医院
    • 皮肤科诊所
    • 美容中心
  • 其他的

8. 全球色素减退治疗市场（依疾病）

  • 白斑
  • 白化病
  • 其他的

9. 全球色素减退治疗市场

  • 市场规模和市场占有率

第十章全球色素减退治疗市场（按地区）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十一章 公司简介

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Bayer AG
  • Candela Corporation
  • Galderma
  • Incyte
  • Novartis AG
  • Pfizer Inc.
  • Pierre Fabre group
  • Shiseido Company Limited
  • 其他的

第十二章 结论

第十三章简称表

第 14 章参考链接

简介目录
Product Code: HLCA25212

Hypopigmentation Disorder Treatment Market Introduction and Overview

According to SPER market research, 'Global Hypopigmentation Disorder Treatment Market Size- By Treatment Type, By Disease Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Hypopigmentation Disorder Treatment Market is predicted to reach 6.11 billion by 2034 with a CAGR 6.36%.

Hypopigmentation disorder treatment focuses on addressing conditions marked by a reduction or loss of melanin, the pigment responsible for skin color. Common conditions include vitiligo, albinism, and post-inflammatory hypopigmentation. The goal of treatment is to restore pigmentation, enhance appearance, and improve overall quality of life.

Restraints: The hypopigmentation disorder treatment market encounters several obstacles that may restrict its growth. A key challenge is the scarcity of curative options, as most treatments aim to manage symptoms rather than deliver lasting results. Patient responses to therapies like topical corticosteroids and phototherapy can vary widely, making it difficult to ensure consistent effectiveness.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Disease Indication

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

AbbVie Inc., Aclaris Therapeutics, Inc., Bayer AG, Candela Corporation, Galderma, Incyte, Novartis AG, Pfizer Inc., Pierre Fabre Group, Shiseido Company Limited.

Global Hypopigmentation Disorder Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Hypopigmentation Disorder Treatment Market is segmented as; Drugs, Procedures.

By Disease Indication: Based on the Disease Indication, Global Hypopigmentation Disorder Treatment Market is segmented as; Vitiligo, Albinism, Other disease indications.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPERs internal database
    • 2.1.4.Premium insight from KOLs
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTERs Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Hypopigmentation Disorder Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hypopigmentation Disorder Treatment Market

7.Global Hypopigmentation Disorder Treatment Market, (USD Million) 2021-2034

  • 7.1.Drugs
    • 7.1.1.Corticosteroids
    • 7.1.2.Melanocyte-stimulating hormone
    • 7.1.3.Other drugs
  • 7.2.Procedures
    • 7.2.1.Laser treatment
    • 7.2.2.Phototherapy
    • 7.2.3.Microdermabrasion
    • 7.2.4.Other procedures
  • 7.3.By end-user
    • 7.3.1.Hospitals
    • 7.3.2.Dermatology clinics
    • 7.3.3.Aesthetic centers
  • 7.4.Other end-users

8.Global Hypopigmentation Disorder Treatment Market, By Disease Indication, (USD Million) 2021-2034

  • 8.1.Vitiligo
  • 8.2.Albinism
  • 8.3.Other disease indications

9.Global Hypopigmentation Disorder Treatment Market, (USD Million) 2021-2034

  • 9.1.Global Hypopigmentation Disorder Treatment Market Size and Market Share

10.Global Hypopigmentation Disorder Treatment Market, By Region, 2021-2034 (USD Million)

  • 10.1.Asia-Pacific
    • 10.1.1.Australia
    • 10.1.2.China
    • 10.1.3.India
    • 10.1.4.Japan
    • 10.1.5.South Korea
    • 10.1.6.Rest of Asia-Pacific
  • 10.2.Europe
    • 10.2.1.France
    • 10.2.2.Germany
    • 10.2.3.Italy
    • 10.2.4.Spain
    • 10.2.5.United Kingdom
    • 10.2.6.Rest of Europe
  • 10.3.Middle East and Africa
    • 10.3.1.Kingdom of Saudi Arabia
    • 10.3.2.United Arab Emirates
    • 10.3.3.Qatar
    • 10.3.4.South Africa
    • 10.3.5.Egypt
    • 10.3.6.Morocco
    • 10.3.7.Nigeria
    • 10.3.8.Rest of Middle-East and Africa
  • 10.4.North America
    • 10.4.1.Canada
    • 10.4.2.Mexico
    • 10.4.3.United States
  • 10.5.Latin America
    • 10.5.1.Argentina
    • 10.5.2.Brazil
    • 10.5.3.Rest of Latin America

11.Company Profile

  • 11.1.AbbVie Inc.
    • 11.1.1.Company details
    • 11.1.2.Financial outlook
    • 11.1.3.Product summary
    • 11.1.4.Recent developments
  • 11.2.Aclaris Therapeutics, Inc.
    • 11.2.1.Company details
    • 11.2.2.Financial outlook
    • 11.2.3.Product summary
    • 11.2.4.Recent developments
  • 11.3.Bayer AG
    • 11.3.1.Company details
    • 11.3.2.Financial outlook
    • 11.3.3.Product summary
    • 11.3.4.Recent developments
  • 11.4.Candela Corporation
    • 11.4.1.Company details
    • 11.4.2.Financial outlook
    • 11.4.3.Product summary
    • 11.4.4.Recent developments
  • 11.5.Galderma
    • 11.5.1.Company details
    • 11.5.2.Financial outlook
    • 11.5.3.Product summary
    • 11.5.4.Recent developments
  • 11.6.Incyte
    • 11.6.1.Company details
    • 11.6.2.Financial outlook
    • 11.6.3.Product summary
    • 11.6.4.Recent developments
  • 11.7.Novartis AG
    • 11.7.1.Company details
    • 11.7.2.Financial outlook
    • 11.7.3.Product summary
    • 11.7.4.Recent developments
  • 11.8.Pfizer Inc.
    • 11.8.1.Company details
    • 11.8.2.Financial outlook
    • 11.8.3.Product summary
    • 11.8.4.Recent developments
  • 11.9.Pierre Fabre group
    • 11.9.1.Company details
    • 11.9.2.Financial outlook
    • 11.9.3.Product summary
    • 11.9.4.Recent developments
  • 11.10. Shiseido Company Limited
    • 11.10.1.Company details
    • 11.10.2.Financial outlook
    • 11.10.3.Product summary
    • 11.10.4.Recent developments
  • 11.11.Others

12.Conclusion

13.List of Abbreviations

14.Reference Links